VIRX Viracta Therapeutics Inc

Price (delayed)

$0.54

Market cap

$21.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.23

Enterprise value

$28M

Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination ...

Highlights
The company's debt fell by 26% QoQ and by 26% YoY
VIRX's EPS is up by 8% YoY and by 7% from the previous quarter
The quick ratio has dropped by 81% year-on-year and by 6% since the previous quarter
The equity has plunged by 78% YoY and by 40% from the previous quarter

Key stats

What are the main financial stats of VIRX
Market
Shares outstanding
39.27M
Market cap
$21.21M
Enterprise value
$28M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.91
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$44.31M
EBITDA
-$43.83M
Free cash flow
-$36.54M
Per share
EPS
-$1.23
Free cash flow per share
-$0.93
Book value per share
$0.28
Revenue per share
$0
TBVPS
$1.05
Balance sheet
Total assets
$41.33M
Total liabilities
$30.25M
Debt
$18.86M
Equity
$11.08M
Working capital
$10.7M
Liquidity
Debt to equity
1.7
Current ratio
1.35
Quick ratio
1.31
Net debt/EBITDA
-0.16
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-79.5%
Return on equity
-191.6%
Return on invested capital
-107.4%
Return on capital employed
-399.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VIRX stock price

How has the Viracta Therapeutics stock price performed over time
Intraday
8%
1 week
14.89%
1 month
-15.63%
1 year
-61.97%
YTD
-5.26%
QTD
0%

Financial performance

How have Viracta Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$52.36M
Net income
-$47.99M
Gross margin
N/A
Net margin
N/A
The net income has grown by 6% from the previous quarter and by 6% YoY
The operating income has declined by 3.3% since the previous quarter

Growth

What is Viracta Therapeutics's growth rate over time

Valuation

What is Viracta Therapeutics stock price valuation
P/E
N/A
P/B
1.91
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
VIRX's EPS is up by 8% YoY and by 7% from the previous quarter
The equity has plunged by 78% YoY and by 40% from the previous quarter
The stock's price to book (P/B) is 6% more than its 5-year quarterly average of 1.8

Efficiency

How efficient is Viracta Therapeutics business performance
The ROE has plunged by 142% YoY and by 32% from the previous quarter
The return on assets has declined by 38% year-on-year and by 11% since the previous quarter
The return on invested capital has declined by 30% since the previous quarter and by 17% year-on-year

Dividends

What is VIRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VIRX.

Financial health

How did Viracta Therapeutics financials performed over time
The company's total assets is 37% higher than its total liabilities
VIRX's current ratio has dropped by 81% year-on-year and by 6% since the previous quarter
The quick ratio has dropped by 81% year-on-year and by 6% since the previous quarter
The company's debt is 70% higher than its equity
The equity has plunged by 78% YoY and by 40% from the previous quarter
The company's debt fell by 26% QoQ and by 26% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.